IE58030B1 - Vaccines based on membrane bound proteins and process for making them - Google Patents

Vaccines based on membrane bound proteins and process for making them

Info

Publication number
IE58030B1
IE58030B1 IE221084A IE221084A IE58030B1 IE 58030 B1 IE58030 B1 IE 58030B1 IE 221084 A IE221084 A IE 221084A IE 221084 A IE221084 A IE 221084A IE 58030 B1 IE58030 B1 IE 58030B1
Authority
IE
Ireland
Prior art keywords
hsv
membrane
derivative
polypeptide
cells
Prior art date
Application number
IE221084A
Other languages
English (en)
Other versions
IE842210L (en
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27414978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IE58030(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IE842210L publication Critical patent/IE842210L/xx
Publication of IE58030B1 publication Critical patent/IE58030B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
IE221084A 1983-08-30 1984-08-29 Vaccines based on membrane bound proteins and process for making them IE58030B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52791783A 1983-08-30 1983-08-30
US54755183A 1983-10-31 1983-10-31
US58817084A 1984-03-09 1984-03-09

Publications (2)

Publication Number Publication Date
IE842210L IE842210L (en) 1985-02-28
IE58030B1 true IE58030B1 (en) 1993-06-16

Family

ID=27414978

Family Applications (1)

Application Number Title Priority Date Filing Date
IE221084A IE58030B1 (en) 1983-08-30 1984-08-29 Vaccines based on membrane bound proteins and process for making them

Country Status (13)

Country Link
US (1) US5851533A (da)
EP (1) EP0139417B2 (da)
JP (2) JP2599350B2 (da)
AU (1) AU579323B2 (da)
CA (1) CA1341181C (da)
DE (1) DE3479085D1 (da)
DK (2) DK172694B1 (da)
ES (2) ES8605039A1 (da)
GR (1) GR80220B (da)
HK (1) HK98792A (da)
IE (1) IE58030B1 (da)
IL (1) IL72785A (da)
NZ (1) NZ209308A (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228501A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung eines herpes-antigens, dazu geeignetes mittel sowie verfahren zu seiner herstellung und die verwendung dieses antigens
NZ209307A (en) * 1983-08-30 1990-07-26 Genentech Inc Diagnostic product: antigenic peptide produced by recombinant dna techniques
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US5612041A (en) * 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US5853978A (en) * 1985-12-04 1998-12-29 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and methods of use
US6534285B1 (en) 1984-12-24 2003-03-18 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
CA1331355C (en) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentation
GR862472B (en) * 1986-09-30 1986-10-09 Elliniko Institouto Paster Determination of antibodies specific of hsv-1 herpes or hsv-2 in human serum with the elisa technic using the specific antigen of hsv-1 or hsv-2 type in semi - clean form
IE81149B1 (en) 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5976839A (en) * 1987-03-13 1999-11-02 Bioenterprises Pty Limited Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules
EP0471778A1 (en) * 1989-05-12 1992-02-26 Ciba Corning Diagnostics Corp. Herpes simplex virus type 2-glycoprotein g proteins and polypeptides
JPH05501951A (ja) * 1989-07-31 1993-04-15 ニコルズ インスティテュート ダイアグノスティクス 組換えヒト甲状腺ペルオキシダーゼ
JP3005292B2 (ja) * 1990-08-02 2000-01-31 カイロン コーポレイション 単純ヘルペスウィルスのvp16のワクチン
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
JPH07506960A (ja) * 1991-08-28 1995-08-03 ニコルス・インスティチュート・ダイアグノスティクス ヒト甲状腺ペルオキシダーゼに特異的な疾病関連性ヒト抗体
JP3755890B2 (ja) * 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス(ソシエテ・アノニム) アジュバント含有ワクチン組成物
US7098025B1 (en) 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
AU2001286407A1 (en) * 2000-08-01 2002-03-04 University Of Pittsburgh Of The Commonwealth System Of Higher Education Antiviral compounds derived from the hsv gd protein and methods
DK2248822T3 (da) 2001-07-27 2017-02-13 Glaxosmithkline Biologicals Sa Meningokokker adhæsiner
JP2004099584A (ja) * 2002-05-02 2004-04-02 Keio Gijuku Hsvを用いた抗腫瘍剤
AU2004274430A1 (en) 2003-09-12 2005-03-31 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
US7540902B2 (en) 2004-11-24 2009-06-02 Shell Oil Company Separator for multi-phase slug flow and method of designing same
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
EP2059255A4 (en) 2006-09-08 2011-08-31 Univ Pennsylvania VACCINES AGAINST HSV-1 AND HSV-2 AND METHODS OF USE
EP2114449B1 (en) * 2006-12-28 2016-02-17 The Trustees of the University of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US10478490B2 (en) 2006-12-28 2019-11-19 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EP3756684A1 (en) * 2009-05-22 2020-12-30 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
NZ600323A (en) 2009-12-03 2013-12-20 Novartis Ag Circulation of components during microfluidization and/or homogenization emulsions
KR101643918B1 (ko) 2009-12-03 2016-07-29 노파르티스 아게 미세 액화를 위한 상호작용 및 배압 챔버의 배치
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
CN102858322B (zh) 2009-12-03 2015-04-29 诺华股份有限公司 疫苗佐剂制备中的亲水过滤
ES2597158T5 (es) 2010-05-12 2020-03-26 Novartis Ag Procedimientos mejorados para preparar escualeno
EP2643014A4 (en) 2010-11-24 2015-11-11 Genocea Biosciences Inc HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE
CA2885693C (en) 2011-11-23 2020-07-28 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
CN110938604B (zh) * 2014-03-03 2024-04-05 阿尔伯特爱因斯坦医学院 重组单纯疱疹病毒2(hsv-2)疫苗载体
EP3226904B1 (en) 2014-12-02 2019-03-06 Novartis AG Manufacture of surfactant-containing compositions
US10350288B2 (en) 2016-09-28 2019-07-16 Genocea Biosciences, Inc. Methods and compositions for treating herpes
AU2021302954A1 (en) 2020-06-30 2023-02-16 Seqirus UK Limited Cold filtration of oil-in-water emulsion adjuvants

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4374127A (en) * 1977-09-19 1983-02-15 Merck & Co., Inc. Herpes sub unit vaccine
FI66020C (fi) * 1977-09-19 1984-08-10 Merck & Co Inc Foerfarande foer framstaellning av antigeniska immunogeniska subunits av hsv-1 och hsv-2
DE2949031A1 (de) * 1978-12-15 1980-07-17 Sandoz Ag Vakzine
FR2480780B1 (fr) * 1980-04-22 1985-12-06 Pasteur Institut Procede de transformation de cellules, notamment eucaryotes, par un adn circulaire tel que celui du virus de l'hepatite b et preparations contenant les produits d'expression desdits adn
EP0038765B1 (fr) * 1980-04-22 1987-09-02 Institut Pasteur Vaccin contre l'hépatite virale B, procédé et cellules eucaryotes transformées pour la production de ce vaccin
US4317811A (en) * 1980-09-11 1982-03-02 Merck & Co., Inc. Herpes simplex type 1 subunit vaccine
WO1982003088A1 (en) * 1981-03-09 1982-09-16 Corp Cetus Vaccines
GB2103622B (en) 1981-06-16 1986-01-15 Genentech Inc Production of foot and mouth disease vaccine from microbially expressed antigens
ZW18282A1 (en) * 1981-08-31 1983-03-23 Genentech Inc Preparation of polypeptides in vertebrate cell culture
US4442205A (en) * 1981-09-22 1984-04-10 The United States Of America As Represented By The Department Of Health And Human Services Simian virus recombinant that directs the synthesis of hepatitis B surface antigen
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4762708A (en) * 1982-02-18 1988-08-09 University Patents, Inc. Materials and methods for herpes simplex virus vaccination
AU1678783A (en) * 1982-07-20 1984-01-26 Molecular Genetics, Inc. Production of herpes simplex viral proteins
US4818694A (en) * 1982-07-20 1989-04-04 American Cyanamid Company Production of herpes simplex viral protein
US4891315A (en) * 1982-10-25 1990-01-02 American Cyanamid Company Production of herpes simplex viral porteins
PT77014B (en) * 1982-07-20 1986-01-24 Molecular Genetics Inc Production of herpes simplex viral proteins
DE3228501A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung eines herpes-antigens, dazu geeignetes mittel sowie verfahren zu seiner herstellung und die verwendung dieses antigens
DK305784A (da) * 1983-06-23 1984-12-24 Stanley Person Ikke-glycosyleret aminosyrekaede af glycoprotein b fra herpes virus type 1 og 2
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US4855224A (en) * 1984-03-09 1989-08-08 Genentech, Inc. Molecularly cloned diagnostic product and method of use
US4618578A (en) * 1984-07-17 1986-10-21 Chiron Corporation Expression of glycoprotein D of herpes simplex virus
EP0175787B1 (en) * 1984-04-06 1995-02-15 Chiron Corporation RECOMBINANT HERPES SIMPLEX gB-gD VACCINE
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
JPS615786A (ja) * 1984-06-19 1986-01-11 Chemo Sero Therapeut Res Inst 単純ヘルペスウイルス遺伝子を組込んだ組換えdna、形質転換動物細胞および単純ヘルペスウイルス蛋白質の製法
DE3582200D1 (de) * 1984-07-20 1991-04-25 Chemo Sero Therapeut Res Inst Rekombinante dns, enthaltend ein herpes-simplex-virus-gen oder ein fragment davon, hefe transformiert mit dieser rekombinanten dns und verfahren zur herstellung von herpes-simplex-virus-proteinen.

Also Published As

Publication number Publication date
DK9197A (da) 1997-01-24
EP0139417A1 (en) 1985-05-02
HK98792A (en) 1992-12-18
GR80220B (en) 1984-11-15
DK172694B1 (da) 1999-05-31
IE842210L (en) 1985-02-28
ES8705036A1 (es) 1987-05-01
JPH08253428A (ja) 1996-10-01
AU579323B2 (en) 1988-11-24
JP2599350B2 (ja) 1997-04-09
US5851533A (en) 1998-12-22
ES552539A0 (es) 1987-05-01
JPS60155128A (ja) 1985-08-15
DE3479085D1 (en) 1989-08-31
DK412284D0 (da) 1984-08-29
EP0139417B1 (en) 1989-07-26
CA1341181C (en) 2001-02-20
IL72785A (en) 1990-07-26
EP0139417B2 (en) 1999-03-17
ES8605039A1 (es) 1986-03-16
DK412284A (da) 1985-04-11
NZ209308A (en) 1991-08-27
AU3242384A (en) 1985-03-07
ES535554A0 (es) 1986-03-16
IL72785A0 (en) 1984-11-30

Similar Documents

Publication Publication Date Title
EP0139417B1 (en) Vaccines based on membrane bound proteins and process for making them
Eisenberg et al. Synthetic glycoprotein D-related peptides protect mice against herpes simplex virus challenge
US5648079A (en) Herpes simplex virus glycoprotein B vaccine
EP0236145B1 (en) Processes for the production of hcmv glycoproteins, antibodies thereto and hcmv vaccines, and recombinant vectors therefor
JP2002136297A (ja) 単純ヘルペスウイルスのvp16のワクチン
Seidel-Dugan et al. C3b receptor activity on transfected cells expressing glycoprotein C of herpes simplex virus types 1 and 2
US4855224A (en) Molecularly cloned diagnostic product and method of use
JP2005333990A (ja) gp350/220非スプライシング変異体
US7264817B1 (en) Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
EP0759995A1 (en) Fusion glycoprotein from hcmv and hsv
AU623375B2 (en) Molecularly cloned diagnostic product and method of use
Landolfi et al. Baculovirus-expressed herpes simplex virus type 2 glycoprotein D is immunogenic and protective against lethal HSV challenge
US20130064844A1 (en) Non-splicing variants of gp350/220
CA1341291C (en) Vaccines based on membrane bound proteins and process for making them
Bröker et al. Escherichia coli-derived envelope protein gD but not gC antigens of herpes simplex virus protect mice against a lethal challenge with HSV-1 and HSV-2
US5674735A (en) DNA encoding the EHV-4 gH or gC glycoprotein
JPH08504592A (ja) 水痘−帯状疱疹ウイルス(vzv)に対するワクチン
AU5013099A (en) Papillomavirus vaccine
AU4889102A (en) Papillomavirus vaccine

Legal Events

Date Code Title Description
MK9A Patent expired